




Zosano Pharma
Investor Relations Department
34790 Ardentech Ct.
Fremont, CA 94555
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ZSAN

| | |
|---------------|---|
| Last Trade: | 0.63 |
| Trade Time: | 4:00 PM ET Dec 13, 2017 |
| Change: | 0.04  (+6.727%) |
| Day Range | 0.60 - 0.64 |
| 52-Week Range | 0.56 - 3.54 |
| Volume | 199,877 |


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company's proprietary transdermal delivery system. The Company's goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 15, 2017

[Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference](#)

Nov 9, 2017

[Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update](#)

Nov 8, 2017

[Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine](#)

Nov 1, 2017

[Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update](#)

Oct 20, 2017

[Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital](#)

Financials [\[View all \]](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)